We seek to make a difference in colorectal cancer treatment
Colorectal cancer is the third most common cancer and the second-leading cause of cancer-related deaths worldwide.1
Approximately 25 percent of patients have metastatic disease at diagnosis, meaning the cancer has spread to distant organs, and about 50 percent will eventually develop metastases, meaning that the cancer has spread from the primary site of origin, or where it started, into different areas of the body.2,3,4 Only 14 percent of patients with metastatic colorectal cancer are expected to survive five years after they are diagnosed.5
Patients with metastatic colorectal cancer may receive surgery (when possible), chemotherapy with or without targeted therapy, and radiation therapy.6,7 The introduction of targeted therapies has helped prolong overall survival in metastatic colorectal cancer compared to chemotherapy.1,8 Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules ("molecular targets") that are involved in the growth, progression, and spread of cancer.11 However, patients eventually may become resistant to these targeted treatments, underscoring the need for continued research for approaches to metastatic colorectal cancer.7, 10,11
We know that that every cancer journey is a unique and personal experience and very complex to be fully understood. We are deeply committed to transforming the lives of people living with colorectal cancer.
References
1 Siegel RL, et al. CA Cancer J Clin. 2020;0:1-20.
2 American Cancer Society. Cancer Facts & Figures 2020. Atlanta: American Cancer Society, 2020.
3 Jeong JH, et al. Clinical Colorectal Cancer. Vol 16. No3, e147-52.
4 www.cancercenter.com/metastasis
5 National Cancer Institute. SEER, Cancer Statistics (1975-2016). Available from: https://seer.cancer.gov/csr/1975_2016/browse_csr.php? sectionSEL=6&pageSEL=sect_06_table.12.
6 Van Cutsem E, et al. Ann Oncol. 2016;27(8):1386-1422.
7 NCCN Clinical Practice Guidelines in Oncology (Colon Cancer). Version 4. 2020.
8 Xie Y-H, et al. Signal Transduct Target Ther. 2020;5:22. https://doi.org/10.1038/s41392-020-0116-z
9 Targeted Cancer Therapies Fact Sheet - National Cancer Institute
10 Lyu H, et al. Acta Pharm Sin B. 2018;8(4):503-510.
11 Baiocchi G, et al. Int J Colorectal Dis. 2009;24(9):1059-1068.
